Fundz

Bausch Health Companies

Laval, Quebec, Canada · Biotechnology, Health Care, Manufacturing

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global, diversified health care company that develops, manufactures and markets a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated health

Key facts

Headquarters
Laval, Quebec, Canada
Employees
7,000
Industries
Biotechnology, Health Care, Manufacturing
Status
Public (BHC)
Website
www.bauschhealth.com
LinkedIn
Company page

Recent activity at Bausch Health Companies

  • : SEC 8-K (5.02):
  • : Bausch Health Companies Inc. Elects New Director Eiry W. Roberts, M.D.
  • : SEC 8-K (5.07): On May 19, 2026, Bausch Health Companies Inc. held its Annual Meeting of Shareholders where shareholders voted on the election of directors. Notably, Dr. Eiry W. Roberts was elected as a new member of the Board of Directors. The directors elected will serve until the company's next Annual Meeting in 2027 or until their successors are appointed. In total, there were 196,814,621 votes for various candidates and a reported 79,859,606 broker non-votes, indicating a significant level of engagement from shareholders during this governance process.
  • : SEC 8-K (5.02): On February 26, 2026, Bausch Health Companies Inc. amended the award agreements for performance share units (PSUs) for executives Thomas Appio and Seana Carson, allowing their earned 2023 PSUs to be paid in cash instead of stock upon vesting. The 2023 PSUs, originally granted in March 2023, are set to vest on March 3, 2026. Specifically, Mr. Appio's agreement involves 1,137,862 PSUs, while Ms. Carson will surrender her 137,922 PSUs for a cash payment based on the market price of the company’s stock on the vesting date. This change aims to adjust the compensation structure for key executives and is noted to have implications on cash flow and stock management strategies.
  • : SEC 8-K (2.02): On February 18, 2026, Bausch Health Companies Inc. announced its results of operations for the quarter and year ended December 31, 2025. This filing includes financial details highlighting performance metrics and other relevant financial information for that period. The announcement also serves as an update to investors and stakeholders regarding the company's financial health and operational results. The press release attached as Exhibit 99.1 provides further breakdowns and analyses of the financial outcomes published on this date.
  • : SEC 8-K (7.01): On January 23, 2026, Bausch Health Companies Inc. announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy. The press release, which is included as Exhibit 99.1 in this filing, outlines significant findings that may impact the company's future strategies and market position regarding treatments for liver conditions. This announcement is deemed relevant for stakeholders as it could influence investment decisions and perceptions of the company's research advancements. The filing explicitly states that this information shall not be considered 'filed' for certain purposes under the Securities Exchange Act.
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01): On January 23, 2026, Bausch Health Companies Inc. announced the results of its global Phase 3 RED-C clinical program, which evaluated amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy. This press release highlights the significance of the clinical results for patients with this serious condition and is considered important information for investors. The announcement follows the completion of the clinical trial program, directly impacting the company's strategies regarding product development in liver disease management. The results may also influence Bausch Health's market positioning and future financial performance.
  • : SEC 8-K (1.01): On January 2, 2026, Bausch + Lomb Corporation entered into the Fourth Amendment to its Credit and Guaranty Agreement, which provides for a new tranche of term loans amounting to $2,802,125,000, maturing in 2031. This amendment is aimed at refinancing its outstanding term B loans due in 2028 and 2031, reducing the applicable interest margins by 0.50% and 0.25%, respectively. The new term loans will have an amortization rate of 1.00% per annum with the first installment due on June 30, 2026. Strategic implications include refinanced debt terms that may positively impact Bausch + Lomb’s financial flexibility and cost of capital moving forward.
  • : SEC 8-K (1.01): On December 26, 2025, Bausch Health Companies Inc. and its wholly owned subsidiary completed exchange offers for the Company's existing 4.875% and 11.00% Senior Secured Notes, totaling $1.6 billion, in exchange for new 10.00% Senior Secured Notes due 2032. This significant agreement was carried out pursuant to the terms outlined in a confidential exchange offer memorandum dated November 24, 2025. The new notes were issued under a supplemental indenture and are fungible with previously issued notes from April 2025. The transaction indicates a strategic restructuring of debt with implications for cash flow and future financing options for the company.

Bausch Health Companies funding history

DateRoundAmount
Jul 2023Funding Round$600.0M

Leadership

  • Scott Solomon, Director, Business Development & Alliance
  • Patricia Rivas Mandujano, Latin America Regional Director, Ethics and Compliance Officer
  • Eiry W. Roberts, M.D., Director
  • Mirza Dautbegovic, Chief Operating Officer
  • Steven Lee, Vice President
  • Jonathan Sadeh, Chief Medical Officer

Verified email and direct lines for Bausch Health Companies’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Bausch Health Companies in the news

Companies similar to Bausch Health Companies

About Bausch Health Companies: questions and answers

What does Bausch Health Companies do?

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global, diversified health care company that develops, manufactures and markets a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated health

Where is Bausch Health Companies headquartered?

Bausch Health Companies is headquartered in Laval, Quebec, Canada.

How many employees does Bausch Health Companies have?

Bausch Health Companies has about 7,000 employees.

Has Bausch Health Companies raised funding?

Yes. Fundz has recorded 1 funding event for Bausch Health Companies. The most recent, Funding Round of $600.0M, was in Jul 2023.

Who leads Bausch Health Companies?

Steven Lee is a Vice President at Bausch Health Companies.

What is the latest news on Bausch Health Companies?

On Jul 01, 2026, SEC 8-K (5.02):

Is Bausch Health Companies a public company?

Yes. Bausch Health Companies is publicly traded under the ticker BHC.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Bausch Health Companies across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.